MICROBAC
LIVE

Serial Number

86698323

Owner

PROBIOTICAL S.P.A.

Attorney

MICHELLE E. TOCHTROP

Filing Date

Jul 20, 2015

Add to watchlist:

No watchlists yet
View on USPTO

MICROBAC Trademark

Serial Number: 86698323 • Registration: 4986679

MICROBAC is a trademark filed by PROBIOTICAL S.P.A. on July 20, 2015. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

PROBIOTICAL S.P.A. (45 trademarks)

Via Mattei, 3

Entity Type: 09

Trademark Details

Filing Date

July 20, 2015

Registration Date

June 28, 2016

Published for Opposition

April 12, 2016

Goods & Services

Micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; Pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; Pharmaceutical products containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; Pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, including, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; Microbial and biological preparations for improving the physical well-being of humans, namely, reducing inflammation and pain; Supplements, namely, dietary supplements, for medical use and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; Supplements, namely, dietary supplements for medical use and baby food, all the above containing liquid, solid, dried or freeze-dried microorganisms or concentrated cultures of probiotic microorganisms; ferments for medical purposes, all the foregoing being for medical and veterinary use only

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 8, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 8, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 8, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 8, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 8, 2025 COAR
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jun 28, 2025 REM2
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Dec 10, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 10, 2024 TCCA
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Dec 10, 2024 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 10, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 10, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 10, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 10, 2024 COAR
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Jul 3, 2023 NAS8
REGISTERED - SEC. 8 (6-YR) ACCEPTED
Jul 3, 2023 8.OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 20, 2023 APRE
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 7, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 7, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 7, 2023 REAP
TEAS SECTION 8 RECEIVED
Dec 27, 2022 ES8R
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 28, 2021 REM1
CORRECTION UNDER SECTION 7 - PROCESSED
Oct 31, 2016 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 31, 2016 APRE
SEC 7 REQUEST FILED
Aug 1, 2016 AMD7
PAPER RECEIVED
Aug 1, 2016 MAIL
REGISTERED-PRINCIPAL REGISTER
Jun 28, 2016 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 12, 2016 NPUB
PUBLISHED FOR OPPOSITION
Apr 12, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 23, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 9, 2016 PREV
ASSIGNED TO LIE
Mar 2, 2016 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 2, 2016 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 2, 2016 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 2, 2016 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 2, 2016 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 2, 2016 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 28, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 28, 2016 CRFA
ASSIGNED TO LIE
Jan 26, 2016 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 13, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 30, 2015 GNRN
NON-FINAL ACTION E-MAILED
Oct 30, 2015 GNRT
NON-FINAL ACTION WRITTEN
Oct 30, 2015 CNRT
ASSIGNED TO EXAMINER
Oct 29, 2015 DOCK
NOTICE OF PSEUDO MARK E-MAILED
Jul 25, 2015 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 24, 2015 NWOS
NEW APPLICATION ENTERED
Jul 23, 2015 NWAP